9 Meters Acquires Investigational Therapy NM-136

9 Meters Acquires Investigational Therapy NM-136

299998

9 Meters Acquires Investigational Therapy NM-136

9 Meters Biopharma acquired global development rights to NM-136, a potential Prader-Willi syndrome (PWS) therapy, from its maker, Lobesity. The therapy candidate, formerly known as LOB-0136, aims to reduce obesity among PWS patients by targeting the glucose-dependent insulinotropic polypeptide (GIP), a molecule that helps sugar enter fat cells. “Continuing to advance NM-136 will be a very important step forward for patients currently living with PWS and suffering from this life-threatening disease,” John Temperato, president and CEO…

You must be logged in to read/download the full post.